Bristol-Myers Squibb Company (BMY) has a MoatMap StockRank of 100/100 based on Quality (68/100), Value (63/100), and Momentum (81/100) factor scores. The current signal is STRONG BUY. Bristol-Myers Squibb represents a compelling 'Durable Compounder at GARP' within the 'Sticky Rates & Defensive Strength' macro environment. As a pharmaceutical giant, it possesses a wide moat derived from patent-protected drugs, a robust R&D pipeline, and strong brand recognition, enabling consistent high ROIC and pricing power. Its defensive sector characteristics provide stability and resilience against economic downturns and elevated interest rates, making it an attractive destination for capital seeking quality and income. The market may not be fully appreciating the defensive strength and long-term compounding potential of such businesses amidst broader market volatility, creating an asymmetric risk-reward.